ClinicalTrials.gg
CompletedNCT02730351Updated Jul 16, 2019Results posted

Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)

A Phase 4 interventional study of Fluticasone furoate/ Vilanterol 100 mcg/25 mcg and Fluticasone propionate 250 mcg in Asthma, sponsored by GlaxoSmithKline. Completed at 16 sites in 2 countries. Open to participants aged 12 Years to 50 Years. Per ClinicalTrials.gov, last updated 2019-07-16.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
12 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
79th of 146
75 · median 100
Started
2016
with 5 others
Phase 4
52 of 147
1 open now
Registered
124th of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 79th largest by enrollment of the 146 interventional ones that give a count, is one of 6 that started in 2016, is one of 52 in phase 4, and was the 124th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, double-dummy, crossover study with two 2-week treatment periods separated by a 2-week wash-out period. Subjects will participate in up to eight study visits and have a follow up phone call approximately a week after the last clinic visit. Visits 1, 2, 3, 5 and 6 are evening visits that will be conducted between 5PM and 11PM. Visit 4 and Visit 7 are also evening visits that will begin between 5PM and 11PM and continue over a period of approximately 24 hours. Subjects will be required to attend three clinic visits during this 24-hour period. An exercise challenge (using a treadmill) will be conducted at Visit 2, Visit 3 and Visit 6 (after 23 hours of the first treatment dose in each Treatment Period); and at 12 and 23 hours post evening dose at Visits 4 and 7. Spirometry will be conducted at specified visits and prior to and after each exercise challenge.

Subjects with symptomatic allergic rhinitis at Visit 1 (screening) may be treated for up to four weeks with intranasal corticosteroids followed by a repeat screening visit to determine eligibility prior to entry into the study.

Eligible subjects at visit 1 will complete a 4-week single blind run-in on FP 250 microgram (mcg) twice daily (BID), followed by 2-week double-blind Treatment Period 1 on randomized treatment, a 2-week single blind washout period on FP 250 mcg BID, 2-week double-blind Treatment Period 2 receiving the alternative treatment, and follow-up contact approximately 7-days after completing Treatment Period 2. The total duration of study participation is approximately 11 weeks; and up to 15 weeks for subjects with Symptomatic Allergic Rhinitis.

The primary objective of the study is to evaluate the protective effect of fluticasone furoate/vilanterol (FF/VI) 100/25 mcg once-daily compared with fluticasone propionate (FP) 250 mcg twice-daily against exercise-induced bronchoconstriction in adolescent and adult subjects aged 12 to 50 with persistent asthma.

ELLIPTA, ACCUHALER, and DISKUS are registered trademarks of the GlaxoSmithKline group of companies.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Fluticasone furoate
  • activity monitoring
  • Vilanterol
  • Cross-over
  • exercise-induced bronchoconstriction
  • exercise challenge
  • double-dummy
  • asthma
  • spirometry
  • fluticasone propionate
04

Who can participate

Ages eligible
12 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • : Subjects must give their signed and dated written informed consent to participate prior to commencing any study related activities.
  • Age Range: 12 to 50 years of age, inclusive, at Visit 1 (Screening).
  • Diagnosis: A diagnosis of asthma, as defined by the National Institutes of Health for at least 12 weeks prior to Visit 1.
  • Asthma Severity: Subjects must have a pre-bronchodilator of >=70 percent of the predicted normal value. Predicted values will be based upon Global Lung Function Initiative equations for spirometry reference values.
  • Evidence of EIB: Subjects must answer "Yes" to at least 2 of the following 3 questions reflecting on the previous 12 months:

    • Are you short of breath during exercise or other physical exertion?
    • Do you wheeze after exercise or other physical exertion?
    • Do you cough after exercise or other physical exertion?
  • Concurrent Anti-Asthma Therapy: Subjects must be taking low- to moderate dose inhaled for 12 weeks prior to Visit 1 in order to participate with no change in dose for the 4 weeks prior to Visit 1.
  • Gender: Subjects may be male or an eligible female. A female is eligible to enter and participate in the study if she is of: Non-child bearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is or surgically sterile).Surgically sterile females are defined as those with a documented hysterectomy and/or bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g., age appropriate, > 45 years, in the absence of hormone replacement therapy.

OR Child bearing potential, has a negative pregnancy test at screening, and agrees to acceptable methods approved in their local country, when used consistently and correctly (i.e., in accordance with the approved product label and the instructions of the physician for the duration of the study - screening to follow-up contact).

  • Albuterol/salbutamol Use: All subjects must be able to replace their current short-acting beta2-agonist with albuterol/salbutamol, to be used only on an as-needed basis for the duration of the study. Each subject must be judged capable of withholding albuterol/salbutamol for at least 6 hours prior to performing spirometric evaluations.
  • Physical Capacity: Each subject must be physically able to perform the exercise challenges on a treadmill when bronchodilators have been withheld.

Exclusion criteria

Exclusion Criteria:

  • Intermittent Asthma, Seasonal Asthma, or Exercise-Induced Bronchoconstriction Only: Subjects with only intermittent or seasonal asthma or only exercise-induced asthma are excluded from participation in this study.
  • History of Life-threatening Asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures within the last 10 years.
  • Asthma Exacerbation: Any asthma exacerbation requiring oral within 12 weeks of Visit 1 or that resulted in an overnight hospitalization requiring additional treatment for asthma within 6 months prior to Visit 1.
  • Symptomatic Allergic Rhinitis: Subjects with symptomatic allergic rhinitis at Visit 1 may be treated for up to four weeks with intranasal corticosteroids followed by a repeat screening visit to determine eligibility prior to entry into the study. Subjects that continue to be symptomatic after up to four weeks of treatment will be excluded.
  • 12-Lead (ECG): A subject is not eligible if he/she has an abnormal, ECG as determined by the investigator at the Screening Visit.
  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of Visit 1 and led to a change in asthma management or, in the opinion of the investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • Concurrent Respiratory Disease: A subject must not have current evidence of:

    1. Atelectasis 2. Bronchopulmonary dysplasia 3. Chronic bronchitis 4. (COPD) (current or past diagnosis including asthma/COPD overlap) 5. Pneumonia 6. Pneumothorax 7. Interstitial lung disease 8. Or any evidence of concurrent respiratory disease other than asthma.
  • Other Concurrent Diseases/Abnormalities: A subject must not have any clinically significant, uncontrolled condition, or disease state that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study.
  • Medications: A subject must not have used any investigational drug within 30 days prior to Visit 1 or within five half-lives (t1/2) of the prior investigational study, whichever is longer of the two periods.
  • Allergies: 1) Drug Allergy: Any adverse reaction including immediate or delayed to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy, or used with FF/VI 100/25 or FP 250 (i.e., drug, lactose or magnesium stearate). 2) Milk Protein Allergy: History of severe milk protein allergy. 3) Latex Allergy: History of allergy or sensitivity to latex that in the opinion of the investigator contraindicates the subject's participation in the study.
  • Concomitant Medication: Administration of prescription or non-prescription medication that would significantly affect the course of asthma, or interact with study drug.
  • Medications: A subject must not be using or require the use of immunosuppressive medications during the study.
  • Compliance: A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability, disease, or geographical location which seems likely (in the opinion of the investigator) to impair compliance with any aspect of this study protocol.
  • Tobacco/Marijuana Use: Current tobacco smoker or has a smoking history of >=10 pack-years (20 cigarettes/day for 10 years). A subject may not have used inhaled tobacco products or inhaled marijuana within the past 3 months (e.g. cigarettes, cigars, electronic cigarettes, or pipe tobacco).
  • Affiliation with Investigator's Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study-coordinator or an employee of the participating investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    FF/VI 100/25 mcg + Placebo DISKUS®/ ACCUHALER®

    Randomised subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS / ACCUHALER for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 2.

    Drug: Fluticasone furoate/ Vilanterol 100 mcg/25 mcg · Drug: Placebo via DISKUS / ACCUHALER

  • Experimental
    FP 250 mcg + Placebo ELLIPTA®

    Randomised subjects will receive FP 250 mcg twice daily via DISKUS inhaler and placebo once daily via ELLIPTA inhaler for 2 weeks in Period 1. There will be a washout period of 2 weeks between treatment periods in which subjects will receive FP 250 mcg twice daily. Subjects will receive FF/VI 100/25 mcg once daily via ELLIPTA inhaler and placebo twice daily via DISKUS inhaler for 2 weeks in Period 2.

    Drug: Fluticasone propionate 250 mcg · Drug: Placebo via ELLIPTA inhaler

Interventions

  • DrugFluticasone furoate/ Vilanterol 100 mcg/25 mcg

    FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening

  • FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening

  • DrugPlacebo via ELLIPTA inhaler

    Placebo will be administered via ELLIPTA inhaler once daily in the evening

  • DrugPlacebo via DISKUS / ACCUHALER

    Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening

06

What researchers measure

Primary outcomes

  1. Maximal Percent Decrease in Forced Expiratory Volume in One Second (FEV1) Following Exercise Challenge at 12 Hours (Hrs) Post Evening Dose From Pre-exercise FEV1.

    The exercise challenge test is a stepped challenge on a treadmill. It was performed at 12 hrs post evening dose at the end of the 2-week treatment period, wherein the participants exercised sufficiently to reach a heart rate between 80 to 95 percent of their predicted maximum within 4 minutes (min) and maintained the heart rate with exercise for an additional 6 min followed immediately by serial assessments of FEV1 at 5, 10, 15, 30, 45 and 60 min post-exercise. Maximal percent decrease was calculated as pre-exercise FEV1 minus minimum post exercise FEV1 (smallest FEV1 value collected within one hr following exercise challenge) divided by pre-exercise FEV1 multiplied by 100. Pre-exercise FEV1 was defined as the FEV1 collected prior to the exercise challenge test at 12 hr post dose. ITT Population comprised of all participants randomized to treatment and who received at least one dose of study medication.

    Time frame: At Week 2 of treatment period 1 and 2

Secondary outcomes

  1. Maximal Percent Decrease in FEV1 Following Exercise Challenge at 23 Hrs Post Evening Dose From Pre-exercise FEV1.

    The exercise challenge test is a stepped challenge on a treadmill. It was performed at 23 hrs post evening dose at the end of the 2-week treatment period, wherein the participants exercised sufficiently to reach a heart rate between 80 to 95 percent of their predicted maximum within 4 min and maintained the heart rate with exercise for an additional 6 min followed immediately by serial assessments of FEV1 at 5, 10, 15, 30, 45 and 60 min post-exercise. Maximal percent decrease was calculated as pre-exercise FEV1 minus minimum post exercise FEV1 (smallest FEV1 value collected within one hr following exercise challenge) divided by pre-exercise FEV1 multiplied by 100. Pre-exercise FEV1 was defined as the FEV1 collected prior to the exercise challenge test at 23 hr post dose.

    Time frame: At Week 2 of treatment period 1 and 2

  2. Proportion of Participants With a 30 Min Post-challenge FEV1 no More Than 5 Percent Lower Than Pre-exercise FEV1 Following the Exercise Challenge at 12 Hrs and 23 Hrs Post Evening Dose.

    The blinded treatment exercise challenge test was performed at the end of 2-weeks of treatment period 1 and treatment period 2 on a treadmill at 12 hrs and 23 hrs after administration of the evening dose of study treatment. The challenge was followed immediately by serial assessments of FEV1 at 5, 10, 15, 30, 45 and 60 min post-exercise. Pre-exercise FEV1 was defined as the FEV1 value collected prior to the exercise challenge test at 23 hrs post-dose. Number of participants listed is the number in the ITT population. Only those participants with data available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: At Week 2 of treatment period 1 and 2

  3. Weighted Mean 0-60 Min for Percentage Decrease From Pre-exercise FEV1 Following Exercise Challenge at 12 Hrs and 23 Hrs Post Evening Dose.

    The exercise challenge testing at the end of 2 week treatment period was performed on a treadmill at 12 hrs and 23 hrs after administration of the evening dose of double-blind treatment. Following exercise challenge testing, post-exercise FEV1 values were assessed serially at 5, 10, 15, 30, 45 and 60 min. Pre-exercise FEV1 was defined as the FEV1 value collected prior to the exercise challenge test at 23 hrs post-dose. Number of participants listed is the number in the ITT population. Only those participants with data available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: At Week 2 of treatment period 1 and 2

07

Results

Posted Oct 13, 2017

Participant flow

This was a multicenter, randomized, double-blind, double-dummy, crossover comparison study of fluticasone furoate (FF)/vilanterol (VI) versus fluticasone propionate (FP) in adolescent and adult participants with asthma and exercise-induced bronchoconstriction (EIB). The study was conducted in two countries-United States and Canada.

Treatment Period 1 (2 Weeks)
Participant flow — Treatment Period 1 (2 Weeks)
MilestoneFF/VI 100/25 µg Followed by FP 250 µgFP 250 µg Followed by FF/VI 100/25 µg
Started3737
Completed3637
Not completed10
Withdrew: Adverse event10
Wash-out Period (2 Weeks)
Participant flow — Wash-out Period (2 Weeks)
MilestoneFF/VI 100/25 µg Followed by FP 250 µgFP 250 µg Followed by FF/VI 100/25 µg
Started3637
Completed3536
Not completed11
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject10
Treatment Period 2 (2 Weeks)
Participant flow — Treatment Period 2 (2 Weeks)
MilestoneFF/VI 100/25 µg Followed by FP 250 µgFP 250 µg Followed by FF/VI 100/25 µg
Started3536
Completed3336
Not completed20
Withdrew: Adverse event10
Withdrew: Lack of efficacy10

Outcome measures

PrimaryMaximal Percent Decrease in Forced Expiratory Volume in One Second (FEV1) Following Exercise Challenge at 12 Hours (Hrs) Post Evening Dose From Pre-exercise FEV1.

The exercise challenge test is a stepped challenge on a treadmill. It was performed at 12 hrs post evening dose at the end of the 2-week treatment period, wherein the participants exercised sufficiently to reach a heart rate between 80 to 95 percent of their predicted maximum within 4 minutes (min) and maintained the heart rate with exercise for an additional 6 min followed immediately by serial assessments of FEV1 at 5, 10, 15, 30, 45 and 60 min post-exercise. Maximal percent decrease was calculated as pre-exercise FEV1 minus minimum post exercise FEV1 (smallest FEV1 value collected within one hr following exercise challenge) divided by pre-exercise FEV1 multiplied by 100. Pre-exercise FEV1 was defined as the FEV1 collected prior to the exercise challenge test at 12 hr post dose. ITT Population comprised of all participants randomized to treatment and who received at least one dose of study medication.

Time frame:
At Week 2 of treatment period 1 and 2
Reported as:
Least squares mean · Percentage of FEV1
Maximal Percent Decrease in Forced Expiratory Volume in One Second (FEV1) Following Exercise Challenge at 12 Hours (Hrs) Post Evening Dose From Pre-exercise FEV1.
Percentage of FEV1FF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUSFP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA
Maximal Percent Decrease in Forced Expiratory Volume in One Second (FEV1) Following Exercise Challenge at 12 Hours (Hrs) Post Evening Dose From Pre-exercise FEV1.15.02 ± 1.05816.71 ± 1.095
Statistical analysis
  • FF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUS vs FP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA · Mixed Models Analysis · p = 0.109 (Mixed model repeated measures analysis adjusted for fixed effects of treatment, sex, age, treatment period, smoking history, period Baseline FEV1 and the mean of the two period Baseline FEV1 values. Subject is fitted as a random effect.) · Mean difference (final values): -1.69 · 95% CI -3.76 to 0.39
SecondaryMaximal Percent Decrease in FEV1 Following Exercise Challenge at 23 Hrs Post Evening Dose From Pre-exercise FEV1.

The exercise challenge test is a stepped challenge on a treadmill. It was performed at 23 hrs post evening dose at the end of the 2-week treatment period, wherein the participants exercised sufficiently to reach a heart rate between 80 to 95 percent of their predicted maximum within 4 min and maintained the heart rate with exercise for an additional 6 min followed immediately by serial assessments of FEV1 at 5, 10, 15, 30, 45 and 60 min post-exercise. Maximal percent decrease was calculated as pre-exercise FEV1 minus minimum post exercise FEV1 (smallest FEV1 value collected within one hr following exercise challenge) divided by pre-exercise FEV1 multiplied by 100. Pre-exercise FEV1 was defined as the FEV1 collected prior to the exercise challenge test at 23 hr post dose.

Time frame:
At Week 2 of treatment period 1 and 2
Reported as:
Least squares mean · Percentage of FEV1
Maximal Percent Decrease in FEV1 Following Exercise Challenge at 23 Hrs Post Evening Dose From Pre-exercise FEV1.
Percentage of FEV1FF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUSFP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA
Maximal Percent Decrease in FEV1 Following Exercise Challenge at 23 Hrs Post Evening Dose From Pre-exercise FEV1.11.90 ± 1.02014.05 ± 1.051
Statistical analysis
  • FF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUS vs FP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA · Mixed Models Analysis · p = 0.051 (Mixed model repeated measures analysis adjusted for fixed effects of treatment, sex, age, treatment period, smoking history, period Baseline FEV1 and the mean of the two period Baseline FEV1 values. Subject is fitted as a random effect.) · Mean difference (final values): -2.15 · 95% CI -4.31 to 0.01
SecondaryProportion of Participants With a 30 Min Post-challenge FEV1 no More Than 5 Percent Lower Than Pre-exercise FEV1 Following the Exercise Challenge at 12 Hrs and 23 Hrs Post Evening Dose.

The blinded treatment exercise challenge test was performed at the end of 2-weeks of treatment period 1 and treatment period 2 on a treadmill at 12 hrs and 23 hrs after administration of the evening dose of study treatment. The challenge was followed immediately by serial assessments of FEV1 at 5, 10, 15, 30, 45 and 60 min post-exercise. Pre-exercise FEV1 was defined as the FEV1 value collected prior to the exercise challenge test at 23 hrs post-dose. Number of participants listed is the number in the ITT population. Only those participants with data available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
At Week 2 of treatment period 1 and 2
Reported as:
Number · Participants
Proportion of Participants With a 30 Min Post-challenge FEV1 no More Than 5 Percent Lower Than Pre-exercise FEV1 Following the Exercise Challenge at 12 Hrs and 23 Hrs Post Evening Dose.
ParticipantsFF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUSFP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA
FEV1 >=95% of pre-exercise FEV1, 12 hrs; n=70, 693429
FEV1 < 95% of pre-exercise FEV1, 12 hrs; n=70, 693640
FEV1 >=95% of pre-exercise FEV1, 23 hrs; n=68, 694237
FEV1 < 95% of pre-exercise FEV1, 23 hrs; n=68, 692632
Statistical analysis
  • FF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUS vs FP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA · Regression, Logistic · p = 0.266 (Repeated measures logistic regression model with parameters estimated using the Generalized Estimating Equation method. Covariates of treatment, sex, age, treatment period, and period baseline FEV1 were included.) · Odds ratio (or): 1.34 · 95% CI 0.80 to 2.2612 hrs: modeling the odds of having FEV1 \>/=95% of pre exercise FEV1 at each of the two time points.
  • FF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUS vs FP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA · Regression, Logistic · p = 0.322 (Repeated measures logistic regression model with parameters estimated using the Generalized Estimating Equation method) · Odds ratio (or): 1.37 · 95% CI 0.73 to 2.5823 hrs: modeling the odds of having FEV1 \>/=95% of pre exercise FEV1 at each of the two time points.
SecondaryWeighted Mean 0-60 Min for Percentage Decrease From Pre-exercise FEV1 Following Exercise Challenge at 12 Hrs and 23 Hrs Post Evening Dose.

The exercise challenge testing at the end of 2 week treatment period was performed on a treadmill at 12 hrs and 23 hrs after administration of the evening dose of double-blind treatment. Following exercise challenge testing, post-exercise FEV1 values were assessed serially at 5, 10, 15, 30, 45 and 60 min. Pre-exercise FEV1 was defined as the FEV1 value collected prior to the exercise challenge test at 23 hrs post-dose. Number of participants listed is the number in the ITT population. Only those participants with data available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
At Week 2 of treatment period 1 and 2
Reported as:
Least squares mean · Percentage of FEV1
Weighted Mean 0-60 Min for Percentage Decrease From Pre-exercise FEV1 Following Exercise Challenge at 12 Hrs and 23 Hrs Post Evening Dose.
Percentage of FEV1FF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUSFP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA
12 hrs post-dose; n=67, 665.87 ± 0.6636.52 ± 0.680
23 hrs post-dose; n=68, 673.98 ± 0.6995.73 ± 0.747
Statistical analysis
  • FF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUS vs FP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA · Mixed Models Analysis · p = 0.342 (Mixed model repeated measures analysis adjusted for fixed effects of treatment, sex, age, treatment period, smoking history, period Baseline FEV1 and the mean of the two period Baseline FEV1 values. Subject is fitted as a random effect.) · Mean difference (final values): -0.65 · 95% CI -2.01 to 0.7112 hrs post-dose
  • FF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUS vs FP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA · Mixed Models Analysis · p = 0.041 (Mixed model repeated measures analysis adjusted for fixed effects of treatment, sex, age, treatment period, smoking history, period Baseline FEV1 and the mean of the two period Baseline FEV1 values.) · Mean difference (final values): -1.75 · 95% CI -3.42 to -0.0723 hrs post-dose

Adverse events

Collected over The on-treatment adverse events (AEs) and serious adverse events (SAEs) were collected from the start of study treatment until the follow-up contact (approximately up to 51 days).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUS0/73 (0%)1/73 (1.4%)5/73 (6.8%)
FP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA0/72 (0%)0/72 (0%)4/72 (5.6%)
Most frequent serious events
Most frequent serious events
EventFF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUSFP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA
GastroenteritisInfections and infestations1/730/72
Most frequent other events
Most frequent other events
EventFF/VI 100/25 µg QD Via ELLIPTA + Placebo BID Via DISKUSFP 250 µg BID Via DISKUS + Placebo QD Via ELLIPTA
Upper respiratory tract infectionInfections and infestations5/734/72

Baseline characteristics

Age, Continuous
Age, Continuous(Years)All Treatment Combined
Mean27.8 ± 10.35
Sex: Female, Male
Sex: Female, Male(Participants)All Treatment Combined
Female43
Male31
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Treatment Combined
Race, Customized — African American/African Heritage28
Race, Customized — Asian - South East Asian Heritage3
Race, Customized — White - White/Caucasian/European Heritage42
Race, Customized — Mixed Race1
08

Study locations

16 sites
  • GSK Investigational Site
    Huntington Beach, California 92647, United States
  • GSK Investigational Site
    Huntington Beach, California 92648, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    Denver, Colorado 80230, United States
  • GSK Investigational Site
    Tallahassee, Florida 32308, United States
  • GSK Investigational Site
    Savannah, Georgia 31406, United States
  • GSK Investigational Site
    Baltimore, Maryland 21236, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27607, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Charleston, South Carolina 29414, United States
  • GSK Investigational Site
    Orangeburg, South Carolina 29118, United States
  • GSK Investigational Site
    El Paso, Texas 79903, United States
  • GSK Investigational Site
    Sherwood Park, Alberta T8H 0N2, Canada
  • GSK Investigational Site
    Mississauga, Ontario L4W 1A4, Canada
  • GSK Investigational Site
    Mississauga, Ontario L5A 3V4, Canada
09

References and documents

Publications

  • Martin N, Weiler JM, Pearlman D, Jacques L, Nunn C, Forth R, West S, Dunn K, O'Byrne PM. Fluticasone furoate/vilanterol versus fluticasone propionate in patients with asthma and exercise-induced bronchoconstriction. J Asthma. 2020 Apr;57(4):431-440. doi: 10.1080/02770903.2019.1579344. Epub 2019 Feb 22. PubMed 30795705 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Feb 2017, 8 months.

Results were first posted in Oct 2017, 8 months after primary completion.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 8 months is below that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2016
First posted
Apr 6, 2016
StartActual
May 25, 2016
Primary completionActual
Feb 3, 2017
CompletionActual
Feb 3, 2017
Results first posted
Oct 13, 2017
Last update
Jul 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02730351
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 6, 2016
Start date
May 25, 2016
Primary completion
Feb 3, 2017
Completion
Feb 3, 2017
Results posted
Oct 13, 2017
Last update
Jul 16, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion